TOLVAPTAN

Search structure
Trade Names:
Synonyms:
Status: Approved (2009)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: C03XA01
UNII: 21G72T1950

Structure
InChI Key GYHCTFXIZSNGJT-UHFFFAOYSA-N
Smile Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1
InChI
InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)

Physicochemical Descriptors

Property Name Value
Molecular Formula C26H25ClN2O3
Molecular Weight 448.95
AlogP 5.68
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 3.0
Polar Surface Area 69.64
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 32.0

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Vasopressin V2 receptor antagonist DailyMed
Primary Target
V2 receptor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Peptide receptor (family A GPCR) Short peptide receptor (family A GPCR) Vasopressin and oxytocin receptor
- 0 - 0 -
Transporter Primary active transporter ATP-binding cassette ABCB subfamily
- 9990 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Heart Failure 4 D006333 ClinicalTrials
Hyponatremia 4 D007010 ClinicalTrials
Heart Failure 4 D006333 ClinicalTrials
Polycystic Kidney Diseases 4 D007690 ClinicalTrials
Dyspnea 3 D004417 ClinicalTrials
Inappropriate ADH Syndrome 3 D007177 ClinicalTrials
Liver Cirrhosis 3 D008103 ClinicalTrials
Polycystic Kidney, Autosomal Dominant 3 D016891 ClinicalTrials
Edema, Cardiac 3 D004489 ClinicalTrials
Carcinoma 2 D002277 ClinicalTrials
Kidney Diseases 2 D007674 ClinicalTrials
Renal Insufficiency, Chronic 2 D051436 ClinicalTrials
Kidney Calculi 1 D007669 ClinicalTrials

Related Entries

Scaffolds

Side Effects from Label

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Investigations
15.17
Metabolism and nutrition disorders
9.8
General disorders and administration site conditions
9.68
Injury, poisoning and procedural complications
7.58
Renal and urinary disorders
6.99
Gastrointestinal disorders
6.14
Hepatobiliary disorders
5.92
Nervous system disorders
5.74
Vascular disorders
4.48
Respiratory, thoracic and mediastinal disorders
4.48
Cardiac disorders
3.69
Infections and infestations
3.38
Psychiatric disorders
2.96
Surgical and medical procedures
2.64
Musculoskeletal and connective tissue disorders
2.49

Cross References

Resources Reference
CAS NUMBER 150683-30-0
ChEBI 32246
ChEMBL CHEMBL344159
DrugBank DB06212
DrugCentral 4110
EPA CompTox DTXSID3048780
FDA SRS 21G72T1950
Guide to Pharmacology 2226
PubChem 216237
SureChEMBL SCHEMBL242421
ZINC ZINC01490477
CONTENTS